Broncus Holding Corp
HKEX:2216
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.46
0.97
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Broncus Holding Corp
Cash & Cash Equivalents
Broncus Holding Corp
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Broncus Holding Corp
HKEX:2216
|
Cash & Cash Equivalents
$83.6m
|
CAGR 3-Years
64%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
A
|
APT Medical Inc
SSE:688617
|
Cash & Cash Equivalents
¥1.3B
|
CAGR 3-Years
120%
|
CAGR 5-Years
70%
|
CAGR 10-Years
N/A
|
|
|
J
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
|
Cash & Cash Equivalents
¥6.5B
|
CAGR 3-Years
35%
|
CAGR 5-Years
57%
|
CAGR 10-Years
36%
|
|
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
Cash & Cash Equivalents
¥20.5B
|
CAGR 3-Years
10%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
J
|
Jafron Biomedical Co Ltd
SZSE:300529
|
Cash & Cash Equivalents
¥1.7B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
|
Cash & Cash Equivalents
¥7.5B
|
CAGR 3-Years
34%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Broncus Holding Corp
Glance View
Broncus Holding Corp. engages in provision of interventional diagnosis and therapeutics solutions. The company is headquartered in Hangzhou, Zhejiang. The company went IPO on 2021-09-24. The firm's business includes providing diagnostic solutions, lung cancer treatment solutions, chronic obstructive pulmonary disease solutions and navigation platforms. The diagnostic solutions pruducts include FleXNeedle, ATV Sheath, ATV Balloon and others. The lung cancer treatment solutions products include InterVapor for lung cancer, H-Marker and others. The chronic obstructive pulmonary disease (COPD) solutions products include InterVapor for COPD and TLD Ablation System. The navigation platform products include Lungpoint, Lungpro, New Generation Navigation Platform and others.
See Also
What is Broncus Holding Corp's Cash & Cash Equivalents?
Cash & Cash Equivalents
83.6m
USD
Based on the financial report for Dec 31, 2023, Broncus Holding Corp's Cash & Cash Equivalents amounts to 83.6m USD.
What is Broncus Holding Corp's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 3Y
64%
Over the last year, the Cash & Cash Equivalents growth was -22%. The average annual Cash & Cash Equivalents growth rates for Broncus Holding Corp have been 64% over the past three years .
You don't have any saved screeners yet
